Nothing Special   »   [go: up one dir, main page]

Schreiber et al., 2009 - Google Patents

Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination

Schreiber et al., 2009

View HTML
Document ID
13158234369909926659
Author
Schreiber T
Deyev V
Rosenblatt J
Podack E
Publication year
Publication venue
Cancer research

External Links

Snippet

Established tumors suppress antitumor immune responses and induce tolerance by incompletely characterized mechanisms, and this phenomenon is an important barrier to tumor immunotherapy. Single vaccination with tumor cells expressing gp96-Ig stimulates …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Marin et al. Cellular senescence is immunogenic and promotes antitumor immunity
Wang et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Buqué et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Campesato et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Yan et al. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Miao et al. Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells
Nam et al. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17
Jing et al. IL6/STAT3 signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung
Han et al. Tumor-induced generation of splenic erythroblast-like Ter-cells promotes tumor progression
Huynh et al. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies
Raeber et al. Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
Hannesdóttir et al. Lapatinib and doxorubicin enhance the S tat1‐dependent antitumor immune response
Cao et al. BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity
Koehn et al. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells
Molenkamp et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients
Yu et al. Scavenger receptors: emerging roles in cancer biology and immunology
Van Deventer et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells
Bald et al. Immune cell–poor melanomas benefit from PD-1 blockade after targeted type I IFN activation
Schuler et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer
Yamazaki et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Sinha et al. Interleukin-13–regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis
González-Martín et al. Maximal T cell–mediated antitumor responses rely upon CCR5 expression in both CD4+ and CD8+ T cells
Vences-Catalán et al. Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells
Yu et al. SOCS3 deficiency in myeloid cells promotes tumor development: involvement of STAT3 activation and myeloid-derived suppressor cells
Xiao et al. IFNγ promotes papilloma development by up-regulating Th17-associated inflammation